We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2011 by Universitätsklinikum Hamburg-Eppendorf.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01156220
First Posted: July 2, 2010
Last Update Posted: April 12, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Universitätsklinikum Hamburg-Eppendorf
  Purpose
In this study the gender specificity of the effects of furosemide in female and male volunteers will be investigated. The healthy volunteers receive 1. furosemide and 2. aminohippurate sodium "PAH" as single dose. The main objective is gender-specific comparison of the pharmacokinetic parameters of furosemide in relation to the effect of furosemide (urinary excretion). Secondary objectives are the gender-specific comparison of renal and systemic PAH clearance with the clearance of furosemide and the influence of various genetic polymorphisms on the variability of furosemide pharmacokinetics.

Condition Intervention Phase
Healthy Male and Female Volunteers Drug: Furosemide Drug: aminohippurate sodium Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers

Resource links provided by NLM:


Further study details as provided by Universitätsklinikum Hamburg-Eppendorf:

Primary Outcome Measures:
  • pharmacokinetic parameter of furosemide (AUC-24) [ Time Frame: day 1 or day 2 ]
    Gender-specific comparison of the pharmacokinetic parameters of furosemide (AUC-24). The sample size calculation for this study was conducted with respect to the expected gender difference in the AUC24 of furosemide.

  • pharmacodynamic parameter of furosemide (Sodium excretion in the urine) [ Time Frame: day 1 or day 2 ]
    Gender-specific comparison of effect of furosemide on urinary excretion (sodium)


Secondary Outcome Measures:
  • pharmacogenetic parameters [ Time Frame: day 1 ]
    Influence of various genetic polymorphism (OAT1, OAT 4, OATP1B1, NKCC2, NCC, ENaC) on the variability of pharmacokinetic of furosemide

  • pharmacokinetic of aminohippuric acid [ Time Frame: day 1 or day 2 ]
    gender-specific comparison of renal and systemic PAH clearance with the clearance of furosemide

  • other pharmacokinetic parameter of furosemide [ Time Frame: day 1 or day 2 ]
    Gender-specific comparison of the other pharmacokinetic parameters of furosemide (Cmax, tmax, t½, CLoral, CLren)

  • other pharmacodynamic parameter of furosemide [ Time Frame: day 1 or day 2 ]
    Gender-specific comparison of effect of furosemide on urinary excretion (chloride, potassium, uric acid, calcium, magnesium, creatinine)


Estimated Enrollment: 40
Study Start Date: January 2012
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: female
The healthy female volunteers receive furosemide and aminohippurate sodium "PAH" as single dose randomised on day 1 or day 2.
Drug: Furosemide
Injection, 40 mg, single dose over 5 min
Other Names:
  • ATC code: C03CA01
  • Product name: Lasix 40 mg Injektionslösung
Drug: aminohippurate sodium
Injection, 500 mg, single dose over 5 min
Other Names:
  • ATC code: V04CH30,
  • Product name: Aminohipppurate Sodium "PAH"
Experimental: male
The healthy male volunteers receive furosemide and aminohippurate sodium "PAH" as single dose randomised on day 1 or day 2
Drug: Furosemide
Injection, 40 mg, single dose over 5 min
Other Names:
  • ATC code: C03CA01
  • Product name: Lasix 40 mg Injektionslösung
Drug: aminohippurate sodium
Injection, 500 mg, single dose over 5 min
Other Names:
  • ATC code: V04CH30,
  • Product name: Aminohipppurate Sodium "PAH"

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteer for medical history and physical examination findings
  • 18 years, <40 years
  • Written informed consent is given
  • No clinically relevant changes in laboratory parameters
  • Inconspicuous current ECG
  • taking medication under a different drug trial within the last 30 days

Exclusion Criteria:

  • concomitant medication at study days or a week before
  • allergies or known hypersensitivity reactions to furosemide or aminohippurate sodium
  • decreased creatinine clearance by Cockcroft-Gault (<100 ml / min)
  • current drug abuses
  • opiate addiction within the last 10 years
  • smoking within the last year
  • pregnancy and 6 months postpartum, lactation
  • deprivation of legal capacity
  • Cooperation inability
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01156220


Contacts
Contact: Ulrike Werner, PD Dr. 040-741055058 uwerner@uke.de

Locations
Germany
Clinical Trial Center North Not yet recruiting
Hamburg, Germany, 20246
Contact: Alen Jambrecina, Dr. med.    +49 40 7410 51603    a.jambrecina@uke.de   
Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
Investigators
Study Director: Thomas Eschenhagen, Prof.Dr.med. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie Universitätsklinikum Hamburg-Eppendorf Martinistr. 52 20246 Hamburg GERMANY
Principal Investigator: Ulrike Werner, PD Dr. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie Universitätsklinikum Hamburg-Eppendorf Martinistr. 52 20246 Hamburg GERMANY
  More Information

Responsible Party: Prof. Dr. med. Thomas Eschenhagen, Institut für Pharmakologie und Toxikologie
ClinicalTrials.gov Identifier: NCT01156220     History of Changes
Other Study ID Numbers: IPT0901
First Submitted: July 1, 2010
First Posted: July 2, 2010
Last Update Posted: April 12, 2011
Last Verified: April 2011

Keywords provided by Universitätsklinikum Hamburg-Eppendorf:
gender, diuretics, furosemide, aminohippuric acid

Additional relevant MeSH terms:
Furosemide
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action